Invesco Portfolio holdings
Invesco Ltd., founded in 1978 and headquartered in Atlanta, Georgia, is a global investment management firm managing hundreds of billions in assets across a diverse range of products, including mutual funds, exchange-traded funds (ETFs), and institutional portfolios. Known for its blend of active and passive investment strategies, Invesco serves individual investors, financial advisors, and institutions, with a strong presence in North America, Europe, and Asia, bolstered by acquisitions like OppenheimerFunds in 2019. The firm offers specialized solutions in equities, fixed income, real estate, and alternatives, leveraging its global research capabilities to cater to varying market needs. Invesco’s commitment to innovation and client-focused investing has solidified its reputation as a versatile player in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adobe
ADBE
|
+$467M |
| 2 |
CRH
CRH
|
+$449M |
| 3 |
Broadcom
AVGO
|
+$446M |
| 4 |
Philip Morris
PM
|
+$414M |
| 5 |
Kenvue
KVUE
|
+$347M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$494M |
| 2 |
ExxonMobil
XOM
|
+$443M |
| 3 |
Visa
V
|
+$433M |
| 4 |
Merck
MRK
|
+$402M |
| 5 |
Advanced Micro Devices
AMD
|
+$388M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.89% |
| 2 | Healthcare | 11.83% |
| 3 | Financials | 11.72% |
| 4 | Industrials | 11.2% |
| 5 | Consumer Discretionary | 10.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ADAP
3676
DELISTED
Adaptimmune Therapeutics
ADAP
| $35.8K | ﹤0.01% |
45,906
+10,914
| +31% | +$9.16K |
|
3677
Workhorse Group
WKHS
$33.4M
| $35.2K | ﹤0.01% |
28
| – | – |
|
3678
Trevi Therapeutics
TRVI
$2.57B
| $35K | ﹤0.01% |
16,046
| – | – |
|
|
AMRN
3679
Amarin Corp
AMRN
$297M
| $35K | ﹤0.01% |
1,901
+167
| +10% | +$3.62K |
|
3680
Redwire
RDW
$1.86B
| $34.4K | ﹤0.01% |
11,907
| – | – |
|
3681
Citius Pharmaceuticals
CTXR
$15.6M
| $33.6K | ﹤0.01% |
1,962
| – | – |
|
3682
Hitek Global
HKIT
$28.1M
| $32.5K | ﹤0.01% |
+4
| New | +$159K |
|
3683
Vor Biopharma
VOR
$1.06B
| $30.8K | ﹤0.01% |
726
| – | – |
|
3684
Ocugen
OCGN
$403M
| $30.7K | ﹤0.01% |
76,797
+3,548
| +5% | +$1.75K |
|
|
NGM
3685
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $30.5K | ﹤0.01% |
28,522
+5,589
| +24% | +$11.6K |
|
3686
BioAtla
BCAB
$5.34M
| $30.4K | ﹤0.01% |
357
+1
| +0.3% | +$127 |
|
|
VXRT
3687
DELISTED
Vaxart
VXRT
| $30.3K | ﹤0.01% |
40,247
+12,975
| +48% | +$9.87K |
|
|
VAXX
3688
DELISTED
Vaxxinity, Inc. Class A Common Stock
VAXX
| $29.8K | ﹤0.01% |
21,761
| – | – |
|
|
GTHX
3689
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $29.8K | ﹤0.01% |
20,697
+6,772
| +49% | +$13.1K |
|
3690
Beyond Air
XAIR
$3.97M
| $29.3K | ﹤0.01% |
32
| – | – |
|
|
LENZ
3691
LENZ Therapeutics
LENZ
$179M
| $29.2K | ﹤0.01% |
1,683
+4
| +0.2% | +$70 |
|
3692
GSI Technology
GSIT
$201M
| $28.8K | ﹤0.01% |
+10,645
| New | +$41.3K |
|
|
OMGA
3693
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $28.8K | ﹤0.01% |
13,372
+42
| +0.3% | +$168 |
|
3694
CytomX Therapeutics
CTMX
$690M
| $28.5K | ﹤0.01% |
22,071
+2,613
| +13% | +$4.11K |
|
3695
Veritone
VERI
$92.9M
| $28.1K | ﹤0.01% |
10,889
| – | – |
|
|
CMRX
3696
DELISTED
Chimerix, Inc.
CMRX
| $27.9K | ﹤0.01% |
29,041
+4,930
| +20% | +$5.37K |
|
|
GRTX
3697
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $27.6K | ﹤0.01% |
157,653
+146,814
| +1,354% | +$182K |
|
3698
OppFi
OPFI
$813M
| $27.5K | ﹤0.01% |
10,925
| – | – |
|
3699
Akebia Therapeutics
AKBA
$338M
| $27.2K | ﹤0.01% |
23,818
-8,174
| -26% | -$10.5K |
|
3700
ProQR Therapeutics
PRQR
$244M
| $27.1K | ﹤0.01% |
20,822
+1,700
| +9% | +$2.67K |
|
Similar funds
Invesco's Q3 2023 Portfolio in Review
As of Q3 2023, Invesco held 3,966 positions worth $371B, down 2.7% from $381B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Invesco's Q3 2023 filing shows 118 new, 2,175 increased, 1,355 reduced and 98 closed positions. Its largest new stake was Stellantis: 12,130,006 shares worth $232M. The largest sale was Microsoft, an estimated $494M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 22% a quarter earlier, followed by Healthcare and Financials.
- Invesco's largest Q3 2023 buy was Stellantis: 12,130,006 shares worth $232M.
- Invesco added most to Adobe in Q3 2023, an estimated $467M increase.
- Invesco's biggest Q3 2023 reduction was Microsoft, cutting an estimated $494M.
- Invesco fully exited Magellan Midstream Partners, L.P. in Q3 2023, selling an estimated $272M.
- Invesco's ten largest holdings make up 14% of its $371B portfolio in Q3 2023.
- Invesco opened 118 new positions and closed 98 in Q3 2023.
- Invesco's portfolio value fell 2.7% quarter-over-quarter to $371B.
Based on Invesco's 13F filing for Q3 2023, filed 13 Nov 2023.